Drug Information

Drug General Information
Drug ID
D0W7SX
Former ID
DIB001048
Drug Name
CNTO-3649
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [522639]
Company
Centocor Ortho Biotech Inc
Target and Pathway
Target(s) Glucagon-like peptide 1 receptor Target Info Agonist [532107]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Insulin secretion
Reactome Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 522639ClinicalTrials.gov (NCT00882726) A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 532107GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One. 2012;7(11):e49152.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.